# **Supplement 2. In- and exclusion criteria**

## **2.1. Eligibility criteria for titles and abstracts**

For the initial review (up to 2022), the first 200 ranked abstracts presented by ASReview were screened independently by two reviewers (TK and LAGvL) using the in- and exclusion criteria stated below. To determine the interrater reliability between the two reviewers, Cohen’s kappa () was calculated. A of 0.81-1.00 was required to continue with independent abstract review. Any potential disagreement was resolved with RPAvE.

**Supplemental table 1. In- and exclusion criteria for titles and abstracts.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Subject** | **Age/species** | **Article/publication type** | **Publication dates** | **Language** | **Sex** |
| **Inclusion criteria** | | | | | |
| Patients with ALS, AD, HD, or PD. | 18 years. | Studies that evaluated barriers and/or facilitators to participation in clinical trial for ALS, AD, HD and/or PD. | 2000-2023 | English, Dutch. | Male and female. |
| **Exclusion criteria** | | | | | |
| Patients with other neurodegenerative diseases, dementias, movement disorders other than ALS, AD, HD and PD. | < 18 years and species other than humans. | Grey literature, incomplete article, such as: unavailability of full text, posters, commentaries, hypothesis articles, articles that are not peer-reviewed. Reviews will also be excluded. | Before 2000 | Other languages than English and Dutch | NA |

Abbreviations: ALS = amyotrophic lateral sclerosis; AD: Alzheimer’s disease; HD = Huntington’s disease; PD = Parkinson’s disease; NA = not available.

## **2.2. Eligibility criteria for full texts**

**Supplemental table 2. Eligibility criteria for full texts**

|  |  |  |
| --- | --- | --- |
| **Content** | **Study design** | **Article type** |
| **Inclusion criteria** | | |
| The primary objective of the study was to identify barriers and/or facilitators to participation in clinical trials for ALS, AD, HD, or PD and/or strategies to overcome barriers/to improve participation of clinical trials in ALS, AD, HD or PD. | - Qualitative research, including, but not limited to: unstructured interviews, semi-structured interviews, focus-groups, open-ended questions.  - Quantitative research, including, but not limited to: surveys, structured interviews. | Complete original articles. |
| **Exclusion criteria** | | |
| Studies that did not investigate barriers and/or facilitators to participation in clinical trials for ALS, AD, HD, and PD. | - Articles that focus on ALS, AD, HD, or PD but also included patients without an official diagnosis.  - Study populations including 50% of patients with ALS, AD, HD, or PD. | Unavailability of full texts. |

Abbreviations: ALS = amyotrophic lateral sclerosis; AD = Alzheimer’s disease; HD = Huntington’s disease; PD = Parkinson’s disease.